Evaluation of in vitro pharmacodynamic drug interactions of ceftazidime-avibactam with tigecycline in ESBL- and carbapenemase producing Escherichia coli and Klebsiella pneumoniae
Our study reveals that the antagonistic interaction between ceftazidime/avibactam and tigecycline can undermine ceftazidime/avibactam's efficacy, suggesting limited clinical benefit in combining these antibiotics. Therefore, further research is encouraged to explore this and alternative combinations or approaches that may offer better clinical outcomes.
Authors
- Jean‐Winoc Decousser (ORCID: https://orcid.org/0000-0001-7105-6202)
- Julien M. Buyck (ORCID: https://orcid.org/0000-0003-0299-4654)
- Mei‐Ling Han (ORCID: https://orcid.org/0000-0002-0861-2437)
- Patrice Nordmann (ORCID: https://orcid.org/0000-0002-1343-1622)
- Niklas Kroemer
- Nicolas Grégoire (ORCID: https://orcid.org/0000-0001-6436-3757)
- Bernhard Drotleff (ORCID: https://orcid.org/0000-0003-0914-6578)
- Aneeq Farooq
- Sebastian G. Wicha (ORCID: https://orcid.org/0000-0002-8773-4845)
- Jian Li (ORCID: https://orcid.org/0000-0001-7953-8230)
- David Schrey
Institutions
- University of Fribourg (CH)
- Inserm (FR)
- Universität Hamburg (DE)
- Université Paris-Est Créteil (FR)
- Discovery Institute (US)
- Paris-Est Sup (FR)
- Australian Regenerative Medicine Institute (AU)
- Université de Poitiers (FR)
- Hamburg Institut (Germany) (DE)
- European Molecular Biology Laboratory (DE)
- Monash University (AU)
- Hamburg University of Technology (DE)
Publication Details
- Journal
- International Journal of Antimicrobial Agents
- Published
- 2025-02-01
- DOI
- https://doi.org/10.1016/j.ijantimicag.2025.107457
- Citations
- 1
- Primary Topic
- Antibiotic Resistance in Bacteria
- Type
- article
- Field-Weighted Citation Impact
- 0.59
Funders
- Deutscher Akademischer Austauschdienst
- Bundesministerium für Bildung und Forschung